Regorafenib (BAY 73-4506) in advanced colorectal cancer: a phase I study
2012; Springer Nature; Volume: 106; Issue: 11 Linguagem: Inglês
10.1038/bjc.2012.153
ISSN1532-1827
AutoresDirk Strumberg, M. E. Scheulen, Beate Schultheis, Heike Richly, Annette Frost, Martin Büchert, O. Christensen, Michael Jeffers, Roland Heinig, Oliver Boix, K. Mross,
Tópico(s)Hepatocellular Carcinoma Treatment and Prognosis
ResumoIn a phase I dose-escalation study, regorafenib demonstrated tolerability and antitumour activity in solid tumour patients. The study was expanded to focus on patients with metastatic colorectal cancer (CRC). Patients received oral regorafenib 60–220 mg daily (160 mg daily in the extension cohort) in cycles of 21 days on, 7 days off treatment. Assessments included toxicity, response, pharmacokinetics and pharmacodynamics. Thirty-eight patients with heavily pretreated CRC (median 4 prior lines of therapy, range 0–7) were enrolled in the dose-escalation and extension phases; 26 patients received regorafenib 160 mg daily. Median treatment duration was 53 days (range 7–280 days). The most common treatment-related toxicities included hand–foot skin reaction, fatigue, voice change and rash. Twenty-seven patients were evaluable for response: 1 achieved partial response and 19 had stable disease. Median progression-free survival was 107 days (95% CI, 66–161). At steady state, regorafenib and its active metabolites had similar systemic exposure. Pharmacodynamic assessment indicated decreased tumour perfusion in most patients. Regorafenib showed tolerability and antitumour activity in patients with metastatic CRC. This expanded-cohort phase I study provided the foundation for further clinical trials of regorafenib in this patient population.
Referência(s)